blog
Last updated: 2019-10-10

Japan Pharmaceutical Information

S
Medical Supporter Team
Cross-border medical coordination and editorial review team
Japan Pharmaceutical Information

Japan Pharmaceutical Information

Japan Pharmaceutical Information

Medical Supporter — Information Notice

This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.

Any specific treatment plan must be assessed by a licensed physician in Japan

Japan Pharmaceutical Information

  • February 19, 2016
  • Read time: 1 minute

On February 12, Japan's Ministry of Health, Labour and Welfare published an announcement that a Pharmaceutical Affairs and Food Sanitation Council Medical Drug Review Meeting Part 2 is scheduled for February 26. The agenda includes:

  • LDK378 (Non-Small Cell Lung Cancer)

  • AZD9291 (Non-Small Cell Lung Cancer)

  • Radium 223 (Prostate Cancer)

  • Ibrutinib (Leukemia)

Ministry of Health, Labour and Welfare webpage:

http://www.mhlw.go.jp/stf/shingi2/0000112329.html

【Important Note】Medical Supporter translates clinical trial data and pharmaceutical information from overseas. This is not intended to encourage participation in clinical trials or use of new drugs. If there are links published by clinical trial units, you can contact them directly. If you're unclear how to reach out, please contact us.

#Lung Cancer #Prostate Cancer #Leukemia

  • Clinical Trial Medications

    (Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Phase II Clinical Trial Results. (Lung Cancer) Is Enhertu Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is Anti-B7-H3 Antibody DS-7300 Effective?

Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Considering medical care in Japan? Need information and support?

We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.

Consult on LINE Contact an advisor
Fukuoka HQ: +81-92-409-5655
Formerly officially certified, No. B-066

Figure 1Figure 1

Figure 2Figure 2

Figure 3Figure 3

Figure 4Figure 4

Related Cancer Information

Related Reading

Cancer Treatment Information

Clinical information, treatment updates, and patient resources for cancer care. Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and Ministry of Economy, Trade and Industry (B-066).

2021-09-23

(Solid Tumors) Is ATR Inhibitor Ceralasertib Effective?

At the ESMO 2021 Congress, Rahul Aggarwal and colleagues from UCSF presented results on the efficacy and safety of the oral ATR inhibitor Ceralasertib, both as a monotherapy and in combination with Lynparza (olaparib), in patients with ARID1A-deficient advanced solid tumors.

2015-09-21

(Solid Tumors) FDA Grants Accelerated Approval for Jemperli in dMMR Advanced Solid Tumors

FDA grants accelerated approval for Jemperli (dostarlimab) for patients with mismatch repair deficient (dMMR) advanced solid tumors that have progressed during or after treatment with no satisfactory alternative.

2019-09-06

(Lung Cancer) Is Ivesa Effective?

ARRIVENT announced results from the FURLONG Phase III trial showing Ivesa (furmonertinib) as first-line treatment for EGFR-mutant NSCLC achieved median PFS of over 20 months, significantly outperforming first-generation EGFR inhibitors.

2022-03-18